Brean Murray Reiterates Buy Rating On NPSP

Brean Murray is reiterating its Buy rating on shares of NPS Pharmaceuticals, Inc. NPSP. “Although there are no additional presentations directly related to Gattex during the 2011 DDW conference, we draw investor attention to several abstracts related to other GLP-2 analog, such as FE 203799 and ZP1848,” Brean Murray writes. NPS Pharmaceuticals closed Wednesday at $9.83.